Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy
Immune checkpoint inhibition (ICI) shows potential for cancer therapies, but response rates vary. Here, the authors use single-cell analyses to show that, in a 28 patient cohort, patients stratified by mucosal-associated invariant T (MAIT) percentages show different response rates, and ICI responder...
Guardado en:
Autores principales: | Sara De Biasi, Lara Gibellini, Domenico Lo Tartaro, Simone Puccio, Claudio Rabacchi, Emilia M. C. Mazza, Jolanda Brummelman, Brandon Williams, Kelly Kaihara, Mattia Forcato, Silvio Bicciato, Marcello Pinti, Roberta Depenni, Roberto Sabbatini, Caterina Longo, Massimo Dominici, Giovanni Pellacani, Enrico Lugli, Andrea Cossarizza |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5dde8cd7955f4749b3113f29084ac913 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Study of Mucosal-Associated Invariant T Cells in Colon Cancer and Roles in Immune Activities
por: Mo J, et al.
Publicado: (2021) -
Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver
por: Pushpa Hegde, et al.
Publicado: (2018) -
T cell activation but not polyfunctionality after primary HIV infection predicts control of viral load and length of the time without therapy.
por: Andrea Cossarizza, et al.
Publicado: (2012) -
Mucosal-associated invariant T cells promote inflammation and intestinal dysbiosis leading to metabolic dysfunction during obesity
por: Amine Toubal, et al.
Publicado: (2020) -
Stabilizing short-lived Schiff base derivatives of 5-aminouracils that activate mucosal-associated invariant T cells
por: Jeffrey Y. W. Mak, et al.
Publicado: (2017)